Adaptive Highlights Updated NCCN MRD Guidance in Multiple Myeloma
SEATTLE, Wash. — September 17, 2026 Adaptive Biotechnologies highlighted updates to the National Comprehensive Cancer Network (NCCN) Guidelines for...
B-ALL
Advertisement
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Eti-cel Data at EHA 2026
NEW YORK, NY, June 11, 2026 Cellectis announced final Phase 1 results from the BALLI-01 clinical trial evaluating lasme-cel,...
Cellectis Secures FDA RMAT Status for Lasme-cel
NEW YORK, June 9, 2026 Cellectis announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine...
BioOra and Cincinnati Advance CAR-T Therapy in Leukemia
Wellington, New Zealand & Cincinnati, Ohio | April 13, 2026 BioOra Limited and Cincinnati Children’s Hospital Medical Center have...
Advertisement
